Literature DB >> 16521063

[Post-stroke depression (II): its differential diagnosis, complications and treatment].

F J Carod-Artal1.   

Abstract

AIM: Post-stroke depression (PSD) is the most frequent neuropsychiatric condition after a stroke. We review the differential diagnosis of PSD, PSD complications and the different therapeutic approaches to PSD. DEVELOPMENT: Differential diagnosis includes post-stroke fatigue and the pseudo-depressive manifestations of strategic infarctions (apathy, aprosody, lack of self psychic activation syndrome, pathological crying syndrome). Functional and cognitive complications of untreated PSD can be observed. Mortality in depressed stroke patients has been estimated between 3.5 and 10 times higher than in non depressed stroke patients; suicide ideation can be observed in 11.3% of stroke patients. Clinical trials controlled with placebo have shown the efficacy of fluoxetine, nortriptiline, trazodone and citalopram in the treatment of PSD. Other therapeutic approaches include cognitive and functional rehabilitation.
CONCLUSION: PSD is a potentially treatable condition, infra-diagnosed, that has a negative effect on cognitive function, functional recovery and survival in stroke patients. State of the art of PSD pharmacological treatment are selective serotonin reuptake inhibitors. However, there are no data showing neither superiority of one specific drug nor the best moment to start treatment.

Entities:  

Mesh:

Year:  2006        PMID: 16521063

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  4 in total

1.  The Role of the Two-Pore Domain Potassium Channel TREK-1 in the Therapeutic Effects of Escitalopram in a Rat Model of Poststroke Depression.

Authors:  Dai-Hua Lin; Xiang-Rong Zhang; Dong-Qing Ye; Guang-Jun Xi; Jiao-Jie Hui; Shan-Shan Liu; Lin-Jiang Li; Zhi-Jun Zhang
Journal:  CNS Neurosci Ther       Date:  2015-02-10       Impact factor: 5.243

2.  Relationship between Depression and Strength Training in Survivors of the Ischemic Stroke.

Authors:  Felipe José Aidar; Dihogo Gama de Matos; Ricardo Jacó de Oliveira; André Luiz Carneiro; Breno Guilherme de Araújo Tinôco Cabral; Paulo Moreira Silva Dantas; Victor Machado Reis
Journal:  J Hum Kinet       Date:  2014-11-12       Impact factor: 2.193

3.  Efficacy and tolerability of pharmacotherapy for post-stroke depression: a network meta-analysis.

Authors:  Linghui Deng; Shi Qiu; Yan Yang; Lu Wang; Yuxiao Li; Jing Lin; Qiang Wei; Lu Yang; Deren Wang; Ming Liu
Journal:  Oncotarget       Date:  2018-01-03

4.  Xingnao Jieyu Decoction Ameliorates Poststroke Depression through the BDNF/ERK/CREB Pathway in Rats.

Authors:  Tao Li; Dou Wang; Bingbing Zhao; Yongmei Yan
Journal:  Evid Based Complement Alternat Med       Date:  2018-10-16       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.